Effect of overexpression of integrin β2 on clinical prognosis in triple negative breast cancer

Abstract

Objective: To investigate the clinical significance of the expression of integrin β2 (ITGB2) and tumor infiltrating dendritic cells CD80 and CD86 in triple negative breast cancer (TNBC). Methods: The expression levels of ITGB2 and MHC-1 in MDA-MB-231 cells and TNBC tissues were detected by Western bolt and RT-PCR, and the expressions of ITGB2, CD80 and CD86 in TNBC tissues were detected by immunohistochemistry. Results: 1.The expression level of ITGB2 in TNBC cell line (1.67±0.38) was higher than that in MCF-10A cell line (1.06±0.38), and the expression level of MHC-1 molecules in TNBC cell line (0.64±0.20) was lower than that in MCF-10A cell line (1.02±0.21). The difference was statistically significant (P=0.036 and 0.020, respectively). 2.The expression level of ITGB2 in TNBC tissues (1.55±0.47) was significantly higher than that in normal breast tissues (1.04±0.31). 3. Immunohistochemistry showed that the expression level of ITGB2 in TNBC tissues (3.31±2.29) was significantly higher than that in paracancerous tissues (1.20±1.19). Combined with clinicopathological data, it was suggested that the expression of ITGB2 was correlated with tumor stage (P=0.038), histological grade (P=0.022), lymph node metastasis (P=0.019), ki67 expression (P=0.000) and total survival (P=0.003). 4. Immunohistochemistry showed that the expression of CD80 and CD86 in TNBC tissues (3.07±1.57, 3.93±1.64) was significantly lower than those in paracancerous tissues (4.63±2.92 vs 5.23±2.85) (P=0.032 and 0.027). Conclusion: The high expression of ITGB2 in triple negative breast cancer affects the prognosis of patients.